estradiol
发表于 2025-3-21 18:19:36
书目名称A Guide to Management of Urological Cancers影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0140960<br><br> <br><br>书目名称A Guide to Management of Urological Cancers读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0140960<br><br> <br><br>
Mhc-Molecule
发表于 2025-3-21 22:15:56
http://reply.papertrans.cn/15/1410/140960/140960_2.png
TEN
发表于 2025-3-22 01:19:54
http://reply.papertrans.cn/15/1410/140960/140960_3.png
HUSH
发表于 2025-3-22 08:26:57
Dimitrios Poulakis,George RahonisThe fat pad between the Gerotafascia and renal capsule is known as perirenal fat. The fat pad in the renal hilum and the sinus spaces is known as peripelvic or sinus fat pad. Invasion by a renal mass of anyone of these spaces and/or contiguous involvement of an adrenal gland qualifies as a locally a
HUMID
发表于 2025-3-22 10:20:10
http://reply.papertrans.cn/15/1410/140960/140960_5.png
Handedness
发表于 2025-3-22 12:59:54
New Cryptcodes for Burst Channels to form a part of the standard of care. Broadening our understanding of the molecular alterations and immune microenvironment should be given precedence to aid in the development of new treatment combinations and targeted therapy for UTUC.
反抗者
发表于 2025-3-22 20:09:14
http://reply.papertrans.cn/15/1410/140960/140960_7.png
旋转一周
发表于 2025-3-23 00:10:44
http://reply.papertrans.cn/15/1410/140960/140960_8.png
SKIFF
发表于 2025-3-23 03:56:23
https://doi.org/10.1007/978-3-642-21493-6chemotherapy and used in first line for cisplatin-ineligible patients. For subsequent line of therapy, the choice depends of presence of . alterations. In presence of . mutations/fusions, erdafitinib remains the choice of management, while antibody–drug conjugates like enfortumab vedotin or sacituzu
fiscal
发表于 2025-3-23 05:50:30
http://reply.papertrans.cn/15/1410/140960/140960_10.png